A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of CMV Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045)

• Status: Not yet recruiting
• Trial end date: 2025-05-13

Summary

The purpose of this study is to evaluate the efficacy and safety of once-a-day orally or IV dose of Letermovir (MK-8228) in Chinese adult Hematopoietic Stem Cell Transplant (HSCT) recipients for the prevention of clinically significant Cytomegalovirus (CMV) Infection.

• Phase: Phase 3

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Treatments: Letermovir